Details of the Drug

General Information of Drug (ID: DMRKU0L)

Drug Name

GS-5718

Synonyms

920036-34-6; tert-Butyl 3-iodo-1H-pyrazolo[3,4-b]pyridine-1-carboxylate; 1-BOC-3-IODO-1H-PYRAZOLO[3,4-B]PYRIDINE; tert-butyl 3-iodopyrazolo[3,4-b]pyridine-1-carboxylate; SCHEMBL3606964; OKKLWSNHFSFXEM-UHFFFAOYSA-N; AMY21637; MFCD13183727; AKOS022178093; GS-5718; PB26872; CS-0048281; FT-0702852; A860172; tert-Butyl3-iodo-1H-pyrazolo[3,4-b]pyridine-1-carboxylate; 1H-Pyrazolo[3,4-b]pyridine-1-carboxylicacid,3-iodo-,1,1-diMethylethylester; 1H-PYRAZOLO[3,4-B]PYRIDINE-1-CARBOXYLIC ACID, 3-IODO-, 1,1-DIMETHYLETHYLESTER

Indication

Disease Entry	ICD 11	Status	REF
Rheumatoid arthritis	FA20	Phase 2	[1]
Cutaneous lupus erythematosus	EB5Z	Phase 1	[2]
------------------------------------------------------------------------------------

Drug Type

Small molecule

Structure

3D MOL

2D MOL

Chemical Identifiers

Formula: C11H12IN3O2
Canonical SMILES: CC(C)(C)OC(=O)N1C2=C(C=CC=N2)C(=N1)I
InChI: InChI=1S/C11H12IN3O2/c1-11(2,3)17-10(16)15-9-7(8(12)14-15)5-4-6-13-9/h4-6H,1-3H3
InChIKey: OKKLWSNHFSFXEM-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 57443610
TTD ID: DF1T2W

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Renal carcinoma antigen NY-REN-64 (IRAK-4)	TTKFVXR	IRAK4_HUMAN	Inhibitor	[3]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	ClinicalTrials.gov (NCT05165771) A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2 Proof-of-Concept Study to Evaluate Safety, Tolerability, and Efficacy of GS-5718 on Background Therapy With Conventional Synthetic Disease-modifying Antirheumatic Drug(s) (csDMARDs) in Participants With Active Rheumatoid Arthritis Who Have an Inadequate Response to Biologic DMARD(s) Treatment. U.S.National Institutes of Health.
2	ClinicalTrials.gov (NCT04809623) A Randomized, Blinded, Placebo-Controlled, Phase 1b Study of GS-5718 in Subjects With Cutaneous Lupus Erythematosus (CLE). U.S.National Institutes of Health.
3	IRAK4 degrader to take on innate immunity. Nat Biotechnol. 2020 Nov;38(11):1221-1223.